JP2023524970A - アミノ酸化合物による呼吸器疾患の治療 - Google Patents

アミノ酸化合物による呼吸器疾患の治療 Download PDF

Info

Publication number
JP2023524970A
JP2023524970A JP2022567249A JP2022567249A JP2023524970A JP 2023524970 A JP2023524970 A JP 2023524970A JP 2022567249 A JP2022567249 A JP 2022567249A JP 2022567249 A JP2022567249 A JP 2022567249A JP 2023524970 A JP2023524970 A JP 2023524970A
Authority
JP
Japan
Prior art keywords
optionally substituted
deuterium
halogen
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022567249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524970A5 (https=
Inventor
エリック ルフェーヴル，
ターナー，スコット
チャ，ジェイコブ
ドン，チェングオ
ホム，ティモシー
ジアン，ラン
レフテリス，カテリーナ
リィ，ホイ
ジュニア，デイビッド ジェイ モーガンズ
ムニョス，マヌエル
ライリー，モーリーン
ジェン，ヤジュン
アンダーソン，クレイグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of JP2023524970A publication Critical patent/JP2023524970A/ja
Publication of JP2023524970A5 publication Critical patent/JP2023524970A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022567249A 2020-05-07 2021-04-30 アミノ酸化合物による呼吸器疾患の治療 Withdrawn JP2023524970A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021674P 2020-05-07 2020-05-07
US63/021,674 2020-05-07
PCT/US2021/030363 WO2021225912A1 (en) 2020-05-07 2021-04-30 Treatment of respiratory diseases with amino acid compounds

Publications (2)

Publication Number Publication Date
JP2023524970A true JP2023524970A (ja) 2023-06-14
JP2023524970A5 JP2023524970A5 (https=) 2024-04-30

Family

ID=78468277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567249A Withdrawn JP2023524970A (ja) 2020-05-07 2021-04-30 アミノ酸化合物による呼吸器疾患の治療

Country Status (10)

Country Link
US (1) US20230181546A1 (https=)
EP (2) EP4520329A3 (https=)
JP (1) JP2023524970A (https=)
KR (1) KR20230049584A (https=)
CN (1) CN115989235A (https=)
AU (1) AU2021268889A1 (https=)
CA (1) CA3173761A1 (https=)
IL (1) IL297969A (https=)
MX (1) MX2022013753A (https=)
WO (1) WO2021225912A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3509590A4 (en) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
EP4247472A4 (en) * 2020-11-19 2024-10-09 Pliant Therapeutics, Inc. INTEGRIN INHIBITORS AND USES THEREOF
MX2023012794A (es) * 2021-04-30 2023-12-15 Pliant Therapeutics Inc Regímenes de dosificación expandidos para inhibidores de integrina.
CN120091811A (zh) * 2022-07-09 2025-06-03 普利安特治疗公司 整合素抑制剂及其与其它药剂组合的用途
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders
WO2024125634A1 (zh) * 2022-12-16 2024-06-20 西藏海思科制药有限公司 一种四氢萘啶类化合物及其在医药上的应用
WO2024235299A1 (zh) * 2023-05-17 2024-11-21 西藏海思科制药有限公司 一种羧基衍生物及其在医药上的应用
WO2025067384A1 (zh) * 2023-09-28 2025-04-03 成都微芯药业有限公司 一类氨基酸整联蛋白抑制剂、其制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513333A (ja) * 1997-08-08 2001-09-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αｖβ６の拮抗物質による急性肺損傷および線維症の治療
US20190276449A1 (en) * 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10204789A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
US9790222B2 (en) * 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
BR112017023432A2 (pt) * 2015-04-30 2018-07-24 Scifluor Life Sciences Inc Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
US10118929B2 (en) * 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
WO2018183795A1 (en) * 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds
BR112021006622A2 (pt) * 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513333A (ja) * 1997-08-08 2001-09-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αｖβ６の拮抗物質による急性肺損傷および線維症の治療
US20190276449A1 (en) * 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BOSCH B: "Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin bl", ANTIVIRAL RES, vol. 69巻3号, JPN7025001502, 2006, pages 173 - 180, ISSN: 0005567888 *
CHEN W: "A potential treatment of COVID-19 with TGF-β blockade", INT J BIOL SCI, vol. 16巻11号, JPN7025001504, 21 April 2020 (2020-04-21), pages 1954 - 1955, ISSN: 0005567890 *
JACKSON T: "The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus", J VIROL, vol. 74巻11号, JPN7025001503, 2000, pages 4949 - 4956, ISSN: 0005567889 *
JOLLY L: "Influenza promotes collagen deposition via αvβ6 integrin-mediated transforming growth factor β ac", J BIOL CHEM, vol. 289巻51号, JPN7025001507, 2014, pages 35246 - 35263, ISSN: 0005567885 *
LIU W: "Integrin αvβ6 mediates epithelial-mesenchymal transition in human bronchial epithelial cells induc", FOLIA MICROBIOL (PRAHA), vol. 65巻2号, JPN7025001501, 26 June 2019 (2019-06-26), pages 329 - 338, ISSN: 0005567887 *
MELIOPOULOS VA: "An Epithelial Integrin Regulates the Amplitude of Protective Lung Interferon Responses against Multi", PLOS PATHOG, vol. 12巻8号, JPN7025001499, 2016, ISSN: 0005567884 *
SIGRIST CJ: "A potential role for integrins in host cell entry by SARS-CoV-2", ANTIVIRAL RES, JPN7025001505, 1 March 2020 (2020-03-01), ISSN: 0005567891 *
WILLIAMS CH: "Integrin alpha v beta 6 is an RGD-dependent receptor for coxsackievirus A9", J VIROL, vol. 78巻13号, JPN7025001500, 2004, pages 6967 - 6973, ISSN: 0005567886 *
WILLIS BC: "Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth f", AM J PATHOL, vol. 166巻5号, JPN7025001498, 2005, pages 1321 - 1332, ISSN: 0005567883 *
田中 明彦: "ＡＲＤＳ（acute respiratory distress syndrome)", 昭和学士会誌, vol. 17巻6号, JPN7025001506, 2017, pages 675 - 681, ISSN: 0005567892 *

Also Published As

Publication number Publication date
EP4520329A2 (en) 2025-03-12
CN115989235A (zh) 2023-04-18
KR20230049584A (ko) 2023-04-13
AU2021268889A1 (en) 2022-12-15
EP4146264A1 (en) 2023-03-15
CA3173761A1 (en) 2021-11-11
US20230181546A1 (en) 2023-06-15
EP4146264A4 (en) 2024-07-24
EP4520329A3 (en) 2025-05-14
WO2021225912A1 (en) 2021-11-11
IL297969A (en) 2023-01-01
MX2022013753A (es) 2023-01-30

Similar Documents

Publication Publication Date Title
JP7273882B2 (ja) アミノ酸化合物および使用方法
US12390463B2 (en) Dosage forms and regimens for amino acid compounds
JP2023524970A (ja) アミノ酸化合物による呼吸器疾患の治療
US20230028658A1 (en) Expanded dosage regimens for integrin inhibitors
HK40106342A (en) Amino acid compounds and methods of use
HK40037094B (en) Amino acid compounds and methods of use
HK40037094A (en) Amino acid compounds and methods of use
BR122024019819A2 (pt) Compostos de aminoácidos, seus usos e composição farmacêutica dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250314

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250407